#Lecanemab #Eisai #Alzheimer's

Exciting Developments at AD/PD™ 2026: Lecanemab Findings

Eisai unveiled plans to present new insights into lecanemab at the upcoming International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026), taking place from March 17 to 21 in Copenhagen, Denmark, and online.

This prestigious event will showcase the latest data on the real-world efficacy and safety of lecanemab, specifically focusing on results from the Clarity AD Open-Label Extension trial spanning four years. Lecanemab represents a major advancement in Alzheimer's treatment, aiming to modify disease progression and enhance the quality of life for patients diagnosed in the early stages.

Professor Lars Lannfelt, co-founder of BioArctic, one of the key developers of lecanemab, will present findings on the mechanisms of action and interaction profiles of the drug. His expertise and groundbreaking research into the Arctic mutation contributing to Alzheimer’s have significantly influenced the treatment landscape.

In addition to insights on lecanemab, BioArctic will also be highlighting their research regarding exidavnemab, particularly its application in Parkinson's disease during the conference. The details of these presentations reflect a commitment to advancing therapeutic options for neurodegenerative diseases, an area of increasing urgency as aging populations worldwide confront rising rates of these conditions.

Schedule of Presentations

The program will feature oral and poster presentations by Eisai and BioArctic, detailing crucial findings related to lecanemab, including:

• - Oral Presentation:

- Title: